IGC
IGC Pharma, Inc.
IGC lost money over the past year, so it has no meaningful PE right now.
IGC Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
IGC's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
IGC PE Valuation
IGC has no meaningful PE right now: it lost money over the past year.
IGC Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| -- | |
| Limited | |
| High |
Analysts expect IGC's revenue to grow, with its earnings and profitability holding steady.
IGC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.08 | $0.00 |
| Q2 2026 | -$0.08 | $0.00 |
| Q1 2026 | -$0.07 | +$0.02 |
| Q4 2025 | -$0.06 | +$0.06 |
| Q3 2025 | -$0.08 | +$0.11 |
| Q2 2025 | -$0.08 | +$0.13 |
| Q1 2025 | -$0.09 | +$0.13 |
| Q4 2024 | -$0.12 | +$0.13 |
IGC is still losing money, but far less than before: $0.08 per share over the past year, against $0.32 at its worst in mid-2022.
IGC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $328K | +72% |
| Q2 2026 | $265K | -19% |
| Q1 2026 | $317K | -3.9% |
| Q4 2025 | $350K | +36% |
| Q3 2025 | $191K | -54% |
| Q2 2025 | $328K | +21% |
| Q1 2025 | $330K | +12% |
| Q4 2024 | $257K | +26% |
IGC's revenue is recovering but still below its 2020 peak: $328,000 last quarter, up 72% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -589% | +929 points |
| Q2 2026 | -1051% | -470 points |
| Q1 2026 | -775% | -348 points |
| Q4 2025 | -840% | -110 points |
| Q3 2025 | -1518% | -1091 points |
| Q2 2025 | -581% | +300 points |
| Q1 2025 | -428% | +308 points |
| Q4 2024 | -731% | +739 points |
IGC's operating margin was −589% last quarter, up 929 points from the same quarter a year ago.
IGC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.4M | +$702K |
| Q2 2026 | -$1.4M | +$60K |
| Q1 2026 | -$1.2M | -$476K |
| Q4 2025 | -$1.2M | +$109K |
| Q3 2025 | -$2.1M | -$1.1M |
| Q2 2025 | -$1.4M | +$375K |
| Q4 2024 | -$1.3M | +$243K |
| Q3 2024 | -$1M | +$593K |
IGC has burned cash in almost every quarter: −$5M over the past year, against −$6M the year before.
IGC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +9.1% | +9.2M shares |
| 1 year | +21% | +19M shares |
| 3 years | +106% | +56.4M shares |
| 5 years | +129% | +61.6M shares |
IGC has 109M diluted shares, up 21% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | — |
IGC Net Leverage
IGC's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
IGC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 30.4 | Neutral |
| Stochastic | 42.1 | Neutral |
IGC's weekly RSI is 30 (neutral) and its Stochastic is 42 (neutral).
IGC PE vs Healthcare Sector
IGC has no meaningful PE right now: it lost money over the past year.
IGC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.24 | 25% below |
| 20 week MA | $0.26 | 31% below |
| 50 week MA | $0.28 | 36% below |
| 100 week MA | $0.31 | 42% below |
| 200 week MA | $0.34 | 47% below |
IGC is in a downtrend: it's below all five of its weekly moving averages, and 47% below its 200-week average.
IGC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $0.61 | $1.75 | +187% |
| 2021 | $1.75 | $1.15 | -34% |
| 2022 | $1.15 | $0.34 | -70% |
| 2023 | $0.34 | $0.28 | -18% |
| 2024 | $0.28 | $0.37 | +32% |
| 2025 | $0.37 | $0.30 | -19% |
| 2026 YTD | $0.30 | $0.18 | -40% |
IGC's yearly returns have swung widely, from +187% in 2020 to −70% in 2022. It's down 40% so far in 2026.